

## Xeloda® (capecitabine) - New and expanded indications

- On December 14, 2022, the <u>FDA approved</u> new indications and updates to the current indications for Genentech's Xeloda (capecitabine). The new indications include:
  - Treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen.
  - Treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen.
  - Adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- The approval of Xeloda for the new indications were derived from studies in the published literature.
- In addition to the new indications, the use of Xeloda for colorectal cancer was expanded to include:
  - Adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen.
  - Perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy.
  - Treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen.
- Xeloda was previously approved for colorectal cancer as a single agent for adjuvant treatment in
  patients with Dukes' C colon cancer who have undergone complete resection of the primary tumor
  when treatment with fluoropyrimidine therapy alone is preferred and as first-line treatment of
  patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone
  is preferred.
- The expanded uses for Xeloda for colorectal cancer were derived from studies in the published literature.
- Xeloda is also approved for treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated and treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy.
- Xeloda carries a boxed warning for increased risk of bleeding with concomitant use of vitamin K antagonists.

## **Optum**

At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.



• The recommended dosage regimens for Xeloda were updated including the option for a lower starting dose for patients with metastatic breast cancer. For complete dosing and administration recommendations, refer to the Xeloda drug label.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.